Canaccord Genuity Group Has Lowered Expectations for Nektar Therapeutics (NASDAQ:NKTR) Stock Price

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) had its price objective decreased by stock analysts at Canaccord Genuity Group from $153.00 to $149.00 in a report issued on Monday, Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Canaccord Genuity Group‘s price target indicates a potential upside of 308.22% from the stock’s current price.

Other analysts also recently issued reports about the company. Wedbush reduced their price objective on Nektar Therapeutics from $80.00 to $50.00 and set a “neutral” rating for the company in a research note on Wednesday, September 23rd. TD Cowen raised Nektar Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Leerink Partners started coverage on Nektar Therapeutics in a research note on Monday, October 12th. They issued an “outperform” rating and a $130.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $185.00 target price on shares of Nektar Therapeutics in a report on Friday, October 2nd. Finally, BTIG Research reissued a “buy” rating and issued a $178.00 target price on shares of Nektar Therapeutics in a report on Friday, October 9th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Nektar Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $130.33.

Get Our Latest Analysis on Nektar Therapeutics

Nektar Therapeutics Trading Down 2.1%

Shares of Nektar Therapeutics stock traded down $0.77 during trading on Monday, reaching $36.50. The company’s stock had a trading volume of 320,642 shares, compared to its average volume of 1,058,947. The company has a 50-day moving average price of $48.47 and a two-hundred day moving average price of $64.54. The firm has a market cap of $1.25 billion, a PE ratio of -5.66 and a beta of 1.44. Nektar Therapeutics has a fifty-two week low of $33.40 and a fifty-two week high of $109.00.

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The biopharmaceutical company reported ($1.63) EPS for the quarter, beating the consensus estimate of ($2.07) by $0.44. Nektar Therapeutics had a negative net margin of 339.67% and a negative return on equity of 29.31%. The firm had revenue of $9.39 million during the quarter, compared to the consensus estimate of $10.27 million. On average, analysts predict that Nektar Therapeutics will post -8.08 earnings per share for the current fiscal year.

Insider Activity at Nektar Therapeutics

In other Nektar Therapeutics news, CEO Howard Robin sold 418 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $71.98, for a total transaction of $30,087.64. Following the sale, the chief executive officer directly owned 54,627 shares in the company, valued at approximately $3,932,051.46. The trade was a 0.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 2.50% of the company’s stock.

Hedge Funds Weigh In On Nektar Therapeutics

Several hedge funds have recently bought and sold shares of the company. Orbimed Advisors LLC purchased a new position in shares of Nektar Therapeutics during the first quarter valued at approximately $19,786,000. Two Seas Capital LP boosted its stake in Nektar Therapeutics by 8.2% in the 3rd quarter. Two Seas Capital LP now owns 3,345,978 shares of the biopharmaceutical company’s stock worth $202,582,000 after buying an additional 253,744 shares during the last quarter. Braidwell LP grew its holdings in Nektar Therapeutics by 112.7% in the 2nd quarter. Braidwell LP now owns 473,617 shares of the biopharmaceutical company’s stock valued at $33,063,000 after buying an additional 250,916 shares during the period. Bank of New York Mellon Corp purchased a new stake in Nektar Therapeutics in the 2nd quarter valued at about $6,706,000. Finally, ACT Capital Partners L.P. purchased a new stake in Nektar Therapeutics in the 3rd quarter valued at about $5,473,000. 75.88% of the stock is owned by hedge funds and other institutional investors.

About Nektar Therapeutics

(Get Free Report)

Nektar Therapeutics is a clinical-stage biopharmaceutical company based in San Francisco, California. It discovers and develops medicines, with a current focus on treatments for autoimmune and inflammatory diseases. Its lead investigational program, rezpegaldesleukin (REZPEG), is designed to stimulate regulatory T cells, which help regulate immune responses. Nektar is studying the candidate in clinical trials for immune-mediated conditions; it is not an approved medicine. Founded in 1990 as Inhale Therapeutic Systems, the company later adopted the Nektar name as it expanded its drug-development work.

Recommended Stories

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.